The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Danchenko I.Y.

Vagner Perm State Medical University

Baidina T.V.

Vagner Perm State Medical University

Kuklina E.M.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Trushnikova T.N.

Wagner Perm State Medical University

Nekrasova I.V.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example of molecules Sema4D and CD72

Authors:

Danchenko I.Y., Baidina T.V., Kuklina E.M., Trushnikova T.N., Nekrasova I.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2): 75‑81

DOI: 10.17116/jnevro202112107275

Views: 1700

Downloaded: 28

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Danchenko IY, Baidina TV, Kuklina EM, Trushnikova TN, Nekrasova IV. Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example of molecules Sema4D and CD72. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2):75‑81. (In Russ.)
https://doi.org/10.17116/jnevro202112107275

 
МСФ на ЯМ
Close metadata
Recommended articles:
Indi­cators of cognitive impairment of varying seve­rity in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):14-20
The first expe­rience with the use of divo­zilimab in the treatment of multiple scle­rosis patients in daily clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):91-95
Predictors of success of in vitro fertilization with cryotransfer in patients with chro­nic endo­metritis acco­rding to laser conversion testing. Russian Journal of Human Reproduction. 2024;(2):62-73
Long-term effi­cacy and safety of divo­zilimab during 2-year treatment of multiple scle­rosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):86-96
Inte­rleukin-6 as a marker of infe­ction gene­ralization in neonatal sepsis. Russian Journal of Anesthesiology and Reanimatology. 2024;(3):35-42
Pecu­liarities of local mRNA gene expression of pro- and anti-inflammatory cyto­kines in term pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):6-13
Prevalence of therapeutic diseases depe­nding on cyto­kines/chemokines levels in people under 45 years. Russian Journal of Preventive Medi­cine. 2024;(7):46-52
Asse­ssment of cyto­kine status in patients with onco­logical diseases and severe COVID-19. Russian Journal of Evidence-Based Gastroenterology. 2024;(3):60-66
The use of algi­nate plates with a complex of anti­microbial peptides and cyto­kines after surgical inte­rventions on periodontal tissues as a prevention of early postoperative complications. Stomatology. 2024;(5):19-23
Local cyto­kine profile of the endo­metrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peri­pheral blood mono­nuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54

OBJECTIVE

To study the expression of Sema4D (CD100), receptor CD72 and a role of Sema4D-CD72-dependent signal in the control of the functions of immunocompetent cells in relapsing-remitting multiple sclerosis (RRMS).

MATERIAL AND METHODS

We studied 76 patients, including 52 with RRMS (41 in remission and 11 in exacerbation), 35 women (67.3%) and 17 men (32.7%) aged 18—55 years, who did not receive disease-modifying drugs, and 24 healthy donors. A controlled clinical and immunological examination of patients with RRMS was carried out proving the involvement of the Sema4D molecule and its CD72 receptor in pathological reactions in this autoimmune disease.

RESULTS AND CONCLUSION

The use of SemaD as a target in the treatment of RRMS is scientifically substantiated. In case of a positive decision on the use of anti-Sema4D drugs, it will be necessary to take into account the effects of semaphorin not only in the central nervous system, but also in the immune system of patients with RRMS.

Keywords:

remitting-relapsing multiple sclerosis
autoimmune pathology
peripheral immune system
semaphorin Sema4D
T-lymphocytes
B-lymphocytes
soluble Sema4D
receptor CD72
Sema4D-CD72-signal
cytokines

Authors:

Danchenko I.Y.

Vagner Perm State Medical University

Baidina T.V.

Vagner Perm State Medical University

Kuklina E.M.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Trushnikova T.N.

Wagner Perm State Medical University

Nekrasova I.V.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Received:

18.07.2019

Accepted:

21.06.2020

List of references:

  1. Boiko AN, Boiko OV, Gusev EI. The choice of the optimal drug for pathogenic treatment of multiple sclerosis: a current state of the problem (a review). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114:10(2):77-91. (In Russ.). https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2/2014/10/downloads/ru/031997-729820141040
  2. Stolyarov ID. The modern methods of diagnostics and treatment of multiple sclerosis. Vestnik Roszdravnadzora. 2010;4:64-67. (In Russ.). https://elibrary.ru/download/elibrary_15195667_39522683.pdf
  3. Karakulova YuV, Zhelnin AV, Trushnikova TN. Epidemiology and geography of multiple sclerosis in the Perm region. Vestnik Roszdravnadzora. 2013;2:43-45. (In Russ.).
  4. Chapoval SP, Vadasz Z, Chapoval AI, Toubi E. Semaphorins 4A and 4D in chronic inflammatory diseases. Inflamm Res. 2017;66:111-117.  https://doi.org/10.1007/s00011-016-0983-5
  5. Kumanogoh A, Marukawa S, Suzuki K, et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature. 2002;419(6907):629-633.  https://doi.org/10.1038/nature01037
  6. Koda T, Okuno T, Takata K, et al. Sema4A inhibits the therapeutic effect of IFN-β in EAE. J Neuroimmunol. 2014;268(1-2):43-49.  https://doi.org/10.1016/j.jneuroim.2013.12.014
  7. De Wit J. Role of semaphorins in the adult nervous system. Prog Neurobiol. 2003;71(2-3):249-267.  https://doi.org/10.1016/j.pneurobio.2003.06.001
  8. Hsieh HH, Chang WT, Yu L, Rao Y. Control of axon-axon attraction by Semaphorin reverse signaling. Proc Natl Acad Sci USA. 2014;111(31):11383-11388. https://doi.org/10.1073/pnas.1321433111
  9. Zhang Y, Liu B, Ma Y, Jin B. Sema 4D/CD100-plexin B is a multifunctional counter-receptor. Cell Mol Immunol. 2013;10(2):97-98.  https://doi.org/10.1038/cmi.2012.65
  10. Kumanogoh A, Suzuki K, Ch’ng E, et al. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J Immunol. 2002;169(3):1175-1181. https://doi.org/10.4049/jimmunol.169.3.1175
  11. Giraudon P, Vincent P, Vuaillat C, et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol. 2004;172(2):1246-1255. https://doi.org/10.4049/jimmunol.172.2.1246
  12. Wang X, Kumanogoh A, Watanabe C, et al. Functional soluble CD100/Sema4D released from activated lymphocytes: possible role in normal and pathologic immune responses. Blood. 2001;97(11):3498-3504. https://doi.org/10.1182/blood.v97.11.3498
  13. Kumanogoh A, Kikutani H. The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol. 2001;22(12):670-676.  https://doi.org/10.1016/s1471-4906(01)02087-7
  14. Tamagnone L, Artigiani S, Chen H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell. 1999;99(1):71-80.  https://doi.org/10.1016/s0092-8674(01)00216-1
  15. Kumanogoh A, Watanabe C, Lee I, et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity. 2000;13(5):621-631.  https://doi.org/10.1016/s1074-7613(00)00062-5
  16. Braley TJ, Segal BM. B-cell Targeting Agents in the Treatment of Multiple Sclerosis. Current Treatment Options in Neurology. 2013;15(3):259-269.  https://doi.org/10.1007/s11940-013-0232-y
  17. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.  https://onlinelibrary.wiley.com/doi/full/10.1002/ana.22366
  18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;6(4):907-911.  https://doi.org/10.1212/wnl.46.4.907
  19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. https://doi.org/10.1212/wnl.33.11.1444
  20. Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol. 2000;7(3):281-289.  https://doi.org/10.1016/s0165-5728(98)91768-4
  21. Baidina TV, Kuklina EM, Trushnikova TN, et al. Pathogenetic and clinical peculiarities of disseminated sclerosis. Perm Medical Journal. 2016;33(4):17-22. (In Russ.).
  22. Kuklina EM, Baidina TV, Danchenko IY, Nekrasova IV. Semaforin Sema4D in the immune system in multiple sclerosis. Bulletin of Experimental Biology and Medicine (English version). 2014;157(2):234-237. (In Russ.). https://doi.org/10.1007/s10517-014-2533-x
  23. Adachi T, Flaswinkel H, Yakura H, et al. The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol. 1998;160(10):4662-4665. https://doi.org/10.1016/s0165-5728(98)91768-4
  24. Kumanogoh A, Kikutani H. Biological functions and signaling of a transmembrane semaphorin, CD100/Sema4D. Cell Mol Life Sci. 2004;61(3):292-300.  https://doi.org/10.1007/s00018-003-3257-7

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.